MOG35-55

Peptide: Properties, Research Applications, and Laboratory Handling

Introduction to MOG35-55

MOG35-55 is a synthetic peptide fragment derived from myelin oligodendrocyte glycoprotein (MOG), a protein expressed on the outer surface of myelin sheaths in the central nervous system. This peptide sequence has become a widely recognized research tool in neuroimmunology due to its role in studying immune-mediated demyelination and central nervous system inflammation.

In laboratory settings, this compound is primarily used to induce experimental autoimmune encephalomyelitis (EAE), a well-established animal model for investigating multiple sclerosis (MS)–like disease mechanisms. Its reliability, reproducibility, and well-characterized immune response profile make it a standard reference material in preclinical research.

What Is MOG35-55?

MOG35-55 represents a specific amino acid sequence (residues 35–55) of the full myelin oligodendrocyte glycoprotein. This region is known to be highly immunogenic, particularly in commonly used laboratory mouse strains such as C57BL/6.

When administered under controlled experimental conditions, the peptide can trigger a T-cell-mediated immune response against myelin antigens. This response leads to inflammation, demyelination, and neurological symptoms that closely resemble aspects of autoimmune neurodegenerative disorders.

Because of these characteristics, the peptide is widely used in academic and pharmaceutical research focused on immune modulation, neuroinflammation, and disease progression modeling.

Role in Neuroimmunology Research

One of the primary applications of this peptide is in the study of autoimmune responses within the central nervous system. Researchers use it to better understand how autoreactive T cells recognize myelin antigens and initiate inflammatory cascades.

Key research areas include:

• T-cell activation and differentiation
• Cytokine signaling pathways
• Blood–brain barrier disruption
• Demyelination and remyelination processes
• Neurodegenerative disease progression

By observing immune responses induced by this peptide, scientists can evaluate potential therapeutic strategies aimed at suppressing or modulating pathological immune activity.

Experimental Autoimmune Encephalomyelitis (EAE) Model

The EAE model is one of the most extensively studied systems in neuroimmunology. The use of this peptide in EAE induction allows for consistent disease onset and predictable clinical scoring.

Researchers value this model because it enables:

• Evaluation of immunosuppressive agents
• Testing of monoclonal antibodies and biologics
• Investigation of antigen-specific tolerance mechanisms
• Longitudinal studies of disease relapse and remission

The reproducibility of results has made this peptide a benchmark compound in preclinical autoimmune research.

Peptide Characteristics and Quality Considerations

High-quality laboratory peptides must meet strict analytical standards. For research reliability, this peptide is typically supplied in lyophilized powder form and characterized using advanced analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry.

Important quality attributes include:

• High purity percentage
• Confirmed molecular weight
• Low endotoxin levels
• Batch-to-batch consistency

These factors are critical to ensuring experimental accuracy and minimizing variability in immune response outcomes.

Handling and Storage Guidelines

Proper handling is essential to maintain peptide stability and integrity. In research laboratories, the peptide is usually reconstituted using sterile solvents under aseptic conditions.

General handling recommendations include:

• Store lyophilized material at low temperatures (typically −20°C or below)
• Avoid repeated freeze–thaw cycles
• Prepare aliquots for single-use applications
• Protect solutions from prolonged light exposure

Adhering to these practices helps preserve biological activity throughout the duration of a study.

Safety and Research-Only Disclaimer

This peptide is intended strictly for laboratory research purposes. It is not approved for human or veterinary use and should only be handled by trained professionals in controlled research environments.

All experimental use must comply with institutional guidelines, ethical standards, and applicable regulatory requirements.

Why Researchers Choose This Peptide

The widespread adoption of this peptide in neuroimmunology research is driven by several factors:

• Extensive validation in peer-reviewed studies
• High relevance to autoimmune disease mechanisms
• Compatibility with established animal models
• Clear and measurable experimental outcomes

These advantages make it a valuable tool for both academic institutions and pharmaceutical development programs.

MOG35-55 plays a critical role in advancing the understanding of autoimmune processes affecting the central nervous system. Through its use in established research models, scientists gain insights into immune dysregulation, neuroinflammation, and potential therapeutic interventions.

When sourced with verified purity and handled correctly, this peptide remains a reliable and indispensable component of modern neuroimmunology research.